Top news of the week: 08.07.2022.
Beyond Animal Testing: How AI is Increasing the Odds in Drug Development
Quris has developed an alternative to testing on animal models, and each one is smaller than the head of a pin. It holds the potential to increase the currently terrible odds in drug ...
Innate's Cancer Therapeutics are Reaching New Clinical Heights
Many of Innate Pharma’s cancer-fighting products are making clinical progress. BioSpace spoke with the company's head of product portfolio strategy and business development, Yannis Morel, ...
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered ...
STEMart Introduces New Antibiotic Potency Tests for Medical Devices
STEMart, a provider of CRO services dedicated to integrated medical device and diagnostic clinical development, introduced new Antibiotic Potency Tests to assess the bioactivity ...
ProteoGenix Doubles R&D Facilities to Pave the Way for Minimal Animal Use in Biologics Development
New facilities support the fast growth and expansion of the phage display, antibody development, and bioproduction platformsSchiltigheim, France: ProteoGenix, a contract research ...
Metagenomics: unlocking the secrets of microbial communities
Metagenomics can now help researchers unlock the secrets of microbial communities and answer exciting research questions.
A guide to manufacturing biologics
Pharma IQ explores the complexities of manufacturing biologics
The Platform that Keeps on Giving: the AstraZeneca/TeneoTwo Deal
BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners' Galym Imanbayev to talk about the AstraZeneca deal and the company's unique business model.